Last reviewed · How we verify
NCT07206914
Geographic Analysis of Cancer Patients' Residences at Delafontaine Hospital
trial in Neoplasms in 300 participants. Not yet recruiting.
15 April 2026
Quick facts
| Lead sponsor | Centre Hospitalier de Saint-Denis |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 15 October 2025 |
| Primary completion | 15 April 2026 |
| Estimated completion | 15 April 2026 |
| Sites | 1 location across France |
Conditions studied
- Neoplasms — all drugs for Neoplasms →
- Oncology Service — all drugs for Oncology Service →
- Health Services Accessibility — all drugs for Health Services Accessibility →
- Health Inequalities — all drugs for Health Inequalities →
Sponsor
Centre Hospitalier de Saint-Denis
Who can join
Eligibility, any sex, with Neoplasms or Oncology Service. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study looks at where cancer patients treated at Delafontaine Hospital live and how far they have to travel for care. By mapping patients' home addresses (anonymized), the research will show how distance, transportation, and social factors affect access to cancer treatments and support services. The goal is to better understand inequalities in access to care and to improve patient support in the future.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07206914
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoplasms
Currently open trials in the same condition.
- NCT07438782 — First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combinatio · Phase 1 · recruiting
- NCT07382817 — Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms · Phase 1 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT07213609 — A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer · Phase 1, PHASE2 · recruiting
Other Centre Hospitalier de Saint-Denis trials
Trials by the same sponsor.
- NCT07204626 — Medical Anthropology and Migrants in Precarious Situations, Cared for in Intensive and Post-intensive Care Units · not yet recruiting
- NCT07200999 — Prevalence of Carriage of Extended-Spectrum Beta-Lactamase (ESBL)-Producing Enterobacteria in Preterm Premature Rupture · not yet recruiting
- NCT07170137 — Comparison of Uterine Distension in Hysterosonography Among Patients Monitored for Infertility · recruiting
- NCT07061561 — Objective Evaluation of Cough Effort in Tracheotomized Patients (LOST Study) · NA · not yet recruiting
- NCT07011017 — Sexual Health of Sub-Saharan African Migrant Women Recently Diagnosed With HIV in Île-de-France: Missed Opportunities fo · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07206914 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier de Saint-Denis
- Last refreshed: 3 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07206914.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing